Analyzing...
Loading company...
Piramal Pharma Ltd. engages in development and manufacturing of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 6,295 full-time employees. The company went IPO on 2022-10-19. The firm has approximately 17 global facilities and a global distribution network in over 100 countries. The firm's subsidiaries include Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business, and the India consumer healthcare business selling over-the-counter products. PPS offers end-to-end development and manufacturing solutions through a globally integrated network of facilities across the drug life cycle to generic companies. PCC's complex hospital product portfolio includes inhalation anesthetics, intrathecal therapies for spasticity and pain management, injectable pain, anesthetics, injectable anti-infectives, and other therapies.
“Operates in Pharmaceuticals — Formulations & API.”
₹8,869 Cr revenue.
COGS 36.5%, employees 27.2%.
“we are moderating our guidance for revenue to be flat for the year and for the EBITDA margins to, moderate to low same, 14.”
“Y o Y decline of three to 4%.”
“I think we'll give more specific guidance later on in the year, but I think we're still holding to the f y thirty numbers.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | -4.0%▼ | 10.3% |
| ROCE | 0.8%▼ | 13.7% |
| Net Margin | -3.6%▼ | 7.6% |
| EBITDA Margin | 10.3%▼ | 15.4% |
| Debt To Equity | 0.67x▲ | 0.15x |
| Rev Growth 3yr | 7.5%▼ | 10.0% |
| EPS Growth 3yr | 20.2%▲ | 16.0% |
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | ₹8,869 Cr -3.1% | ₹9,151 Cr +12.0% | ₹8,171 Cr +15.4% | ₹7,082 Cr |
| Other Income | ₹213 Cr +58.2% | ₹135 Cr -23.1% | ₹175 Cr -22.1% | ₹225 Cr |
| Total Income | ₹9,082 Cr -2.2% | ₹9,286 Cr +11.3% | ₹8,347 Cr +14.2% | ₹7,307 Cr |
| COGS | ₹3,239 Cr +0.2% | ₹3,232 Cr +9.4% | ₹2,954 Cr +9.3% | ₹2,703 Cr |
| ₹9,119 Cr +2.0% | ₹8,944 Cr +9.6% | ₹8,164 Cr +9.2% | ₹7,474 Cr | |
| Profit Before Tax | (₹233 Cr) ↓ Decline | ₹342 Cr +185.2% | ₹120 Cr ↑ Recovery | (₹174 Cr) |
| Exceptional Items | (₹196 Cr) | ₹0.00 Cr +100.0% | (₹63 Cr) -802.2% | (₹7 Cr) |
| ₹150 Cr -53.7% | ₹324 Cr +100.4% | ₹161 Cr +143.5% | ₹66 Cr | |
| Net Profit | (₹326 Cr) ↓ Decline | ₹91 Cr +411.4% | ₹18 Cr ↑ Recovery | (₹186 Cr) |
| Profit (Owners) | (₹326 Cr) ↓ Decline | ₹91 Cr +411.4% | ₹18 Cr ↑ Recovery | (₹186 Cr) |
| Other Comprehensive Income | ₹338 Cr +323.9% | ₹80 Cr +40.7% | ₹57 Cr -67.7% | ₹176 Cr |
| EPS | (₹2.45) | ₹0.69 | ₹0.13 | (₹1.41) |
| Diluted Shares | ₹133 Cr | ₹133 Cr | ₹132 Cr | ₹132 Cr |
| Profit Or Loss Of Associates | ₹57 Cr -21.6% | ₹73 Cr +22.6% | ₹59 Cr +9.5% | ₹54 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Piramal Pharma Limited has informed the Exchange about Transcript
Proceedings and Voting Results of the 6th Annual General Meeting of the Company
Piramal Pharma Limited has informed the Exchange about Link of Recording
Piramal Pharma Limited has informed the Exchange about Presentation
Piramal Pharma Limited has informed the Exchange about Investor Presentation
Piramal Pharma Limited has informed the Exchange regarding a press release dated July 29, 2026, titled "Piramal Pharma Limited Announces Results for Q1 FY27".
Piramal Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 -Grant of stock options pursuant to Piramal Pharma Limited - Employee St...
Please refer attachment.
Piramal Pharma Limited has informed the Exchange about Schedule of meet
Ajay G. Piramal has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2...
Piramal Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Newspaper Advertisement for information regarding 6th Annual General Meeting of the Company
Permanent revocation of closure directions for Company s Dahej Site
Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015